These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 30730936)
1. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio. Toledano MN; Vera P; Tilly H; Jardin F; Becker S PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936 [TBL] [Abstract][Full Text] [Related]
2. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231 [TBL] [Abstract][Full Text] [Related]
3. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma. Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092 [TBL] [Abstract][Full Text] [Related]
4. Prognostic analysis of interim Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301 [TBL] [Abstract][Full Text] [Related]
5. Predictive value of Dmax and %ΔSUVmax of Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837 [TBL] [Abstract][Full Text] [Related]
6. [Values of Different Evaluation Criteria of Interim Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax. Zhang XY; Song L; Wang PJ; Wang L; Li Y; Wang YY; Shi CL Acta Haematol; 2020; 143(2):124-130. PubMed ID: 31382264 [TBL] [Abstract][Full Text] [Related]
8. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. Itti E; Meignan M; Berriolo-Riedinger A; Biggi A; Cashen AF; Véra P; Tilly H; Siegel BA; Gallamini A; Casasnovas RO; Haioun C Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1312-20. PubMed ID: 23649463 [TBL] [Abstract][Full Text] [Related]
9. Can the SUV Zhang Y; Fan Y; Ying Z; Song Y; Zhu J; Yang Z; Wang X Leuk Lymphoma; 2018 Mar; 59(3):660-669. PubMed ID: 28771052 [TBL] [Abstract][Full Text] [Related]
10. Validation of the ΔSUV Itti E; Blanc-Durand P; Berriolo-Riedinger A; Kanoun S; Kraeber-Bodéré F; Meignan M; Gat E; Gouill SL; Casasnovas RO; Bodet-Milin C J Nucl Med; 2023 Nov; 64(11):1706-1711. PubMed ID: 37734837 [TBL] [Abstract][Full Text] [Related]
11. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial. Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651 [TBL] [Abstract][Full Text] [Related]
12. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053 [TBL] [Abstract][Full Text] [Related]
13. [Prognostic Value of Interim PET/CT in 227 Patients of DLBCL]. Wang RM; Li F; Liu CB; Guan ZW; Fu LP; Xu BX; Zhu HY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):74-79. PubMed ID: 30738450 [TBL] [Abstract][Full Text] [Related]
14. Interobserver Agreement of Interim and End-of-Treatment Burggraaff CN; Cornelisse AC; Hoekstra OS; Lugtenburg PJ; De Keizer B; Arens AIJ; Celik F; Huijbregts JE; De Vet HCW; Zijlstra JM; J Nucl Med; 2018 Dec; 59(12):1831-1836. PubMed ID: 29728515 [TBL] [Abstract][Full Text] [Related]
15. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma. Wight J; Wai SH; Shen E; Lee ST; Berlangieri S; Fancourt T; Hawkes E; Hannah A; Leung T; Chong G Eur J Haematol; 2021 Oct; 107(4):475-483. PubMed ID: 34240453 [TBL] [Abstract][Full Text] [Related]
16. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV Annunziata S; Cuccaro A; Tisi MC; Hohaus S; Rufini V Ann Nucl Med; 2018 Jun; 32(5):372-377. PubMed ID: 29464479 [TBL] [Abstract][Full Text] [Related]
17. Burggraaff CN; Eertink JJ; Lugtenburg PJ; Hoekstra OS; Arens AIJ; de Keizer B; Heymans MW; van der Holt B; Wiegers SE; Pieplenbosch S; Boellaard R; de Vet HCW; Zijlstra JM; J Nucl Med; 2022 Jul; 63(7):1001-1007. PubMed ID: 34675112 [TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma]. Ding CY; Guo Z; Sun J; Yang WP; Li TR Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362 [No Abstract] [Full Text] [Related]
19. Predicting diffuse large B-cell lymphoma outcomes with lesion-to-liver maximum standardized uptake value for interim-treatment and end-of-treatment positron emission tomography-computed tomography. Wang L; Zhang S; Xin J Quant Imaging Med Surg; 2023 Oct; 13(10):6789-6800. PubMed ID: 37869355 [TBL] [Abstract][Full Text] [Related]
20. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUV Rekowski J; Hüttmann A; Schmitz C; Müller SP; Kurch L; Kotzerke J; Franzius C; Weckesser M; Bengel FM; Freesmeyer M; Hertel A; Krohn T; Holzinger J; Brink I; Haberkorn U; Nyuyki F; van Assema DME; Geworski L; Hasenclever D; Jöckel KH; Dührsen U J Nucl Med; 2021 Jan; 62(1):37-42. PubMed ID: 32385164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]